Neuroblastoma (pediatric Cancer: Diagnosis, Therapy, And Prognosis, Vol. 1)
by M.A. Hayat /
2011 / English / PDF
3.8 MB Download
Introduction of new technologies and their applications to
neuroblastoma diagnosis, treatment, and therapy assessment are
explained. Role of molecular ghenetics in diagnosis and therapy for
neuroblastoma patients is detailed. Molecular detection of minimal
residual neuroblastoma is described. Magnetic resonance imaging
and spectroscopy are detailed for diagnosing this solid,
extracranial cancer. Targets for therapeutic intervention in
neuroblastoma are identified, including targeting multidrug
resistance in this cancer. Ornithine decarboxylase and polyamines
are novel targets for therapeutic intervention. The effectiveness
of chemotherapy with oral irinotecan and temozolomide is explained.
The role of transcription factors (GATA) in neuroblastoma
pregression is also included.
Introduction of new technologies and their applications to
neuroblastoma diagnosis, treatment, and therapy assessment are
explained. Role of molecular ghenetics in diagnosis and therapy for
neuroblastoma patients is detailed. Molecular detection of minimal
residual neuroblastoma is described. Magnetic resonance imaging
and spectroscopy are detailed for diagnosing this solid,
extracranial cancer. Targets for therapeutic intervention in
neuroblastoma are identified, including targeting multidrug
resistance in this cancer. Ornithine decarboxylase and polyamines
are novel targets for therapeutic intervention. The effectiveness
of chemotherapy with oral irinotecan and temozolomide is explained.
The role of transcription factors (GATA) in neuroblastoma
pregression is also included.